UBS lowered the firm’s price target on Blend Labs (BLND) to $3.50 from $4 and keeps a Neutral rating on the shares. Blend continues to face a well-understood challenging mortgage backdrop and focus is shifting towards consumer banking, the analyst tells investors in a research note.